<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://pharmadog.xyz/news/368972</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-05T16:51:00.000Z</news:publication_date>
      <news:title>Novartis and Ionis&apos;s pelacarsen fails to cut heart events despite lowering Lp(a) levels</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/367075</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-05T10:00:45.000Z</news:publication_date>
      <news:title>Novartis pauses CAR-T trials after three patient deaths</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/366903</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-05T08:30:00.000Z</news:publication_date>
      <news:title>STAT readers weigh in on MD vs DO training, AI accountability and surrogacy in medicine</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/366691</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-05T07:42:51.000Z</news:publication_date>
      <news:title>ADARx Pharmaceuticals, backed by AbbVie, files for IPO with three RNAi drugs in clinical trials</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/364943</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T21:07:27.000Z</news:publication_date>
      <news:title>Novartis&apos; experimental heart drug pelacarsen fails pivotal Phase 3 trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/365730</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T20:47:00.000Z</news:publication_date>
      <news:title>Novartis&apos; Lp(a) drug pelacarsen fails to cut heart attack or stroke risk in phase 3 trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/365031</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T20:18:49.000Z</news:publication_date>
      <news:title>FDA issues guidance to prevent newborn nutrition supply gap</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/365032</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T19:38:04.000Z</news:publication_date>
      <news:title>FDA grants accelerated approval for Etcamah combo therapy for advanced HR-positive, HER2-negative breast cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/364027</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T16:05:04.000Z</news:publication_date>
      <news:title>Mass General Brigham drops Dana-Farber from its Medicare Advantage network starting Oct 1</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/364067</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T16:00:00.000Z</news:publication_date>
      <news:title>AbbVie’s dual-acting myeloma drug etentamig meets main Phase 3 goal, showing longer progression-free survival</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/364068</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T15:56:31.000Z</news:publication_date>
      <news:title>Licensing deals with Chinese biotech stay strong as big pharma pours $550M+ into cancer and obesity pipelines</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/364028</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T15:34:42.000Z</news:publication_date>
      <news:title>Experts say Angelman syndrome drug failure leaves hope for similar antisense therapies</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/363963</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T15:34:26.000Z</news:publication_date>
      <news:title>Funding shortfall threatens progress of new Ebola vaccine candidates</news:title>
    </news:news>
  </url>
</urlset>
